Abbott Laboratories (ABT) EVP reports 5,314-share trust move

Rhea-AI Filing Summary

Abbott Laboratories executive Mary K. Moreland, an Executive Vice President, reported updated holdings of common shares. A discretionary transaction under Rule 16b-3(f) involved 5,314 common shares in a Profit Sharing Trust at $94.41 per share, leaving 17,159 shares held indirectly in the trust as of April 28, 2026. A separate holding entry shows 104,291 common shares held directly in her name. A footnote describes this as the balance in the Abbott Laboratories Stock Retirement Trust as of that date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Moreland Mary K

Role EXECUTIVE VICE PRESIDENT

Type	Security	Shares	Price	Value
I	Common shares without par value	5,314	$94.41	$502K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 17,159 shares (Indirect, Profit Sharing Trust); Common shares without par value — 104,291 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Discretionary transaction shares: 5,314 shares Transaction price: $94.41 per share Indirect trust holdings: 17,159 shares +1 more

4 metrics

Discretionary transaction shares 5,314 shares Common shares in Profit Sharing Trust under Rule 16b-3(f)

Transaction price $94.41 per share Price for 5,314 common shares in trust transaction

Indirect trust holdings 17,159 shares Common shares held indirectly in Profit Sharing Trust after transaction

Direct holdings 104,291 shares Common shares held directly by Mary K. Moreland as of April 28, 2026

Key Terms

Discretionary transaction, Rule 16b-3(f), Profit Sharing Trust, Stock Retirement Trust

4 terms

Discretionary transaction financial

"transaction_action": "discretionary transaction""

Rule 16b-3(f) regulatory

"transaction_code_description": "Discretionary transaction under Rule 16b-3(f)""

Profit Sharing Trust financial

"nature_of_ownership": "Profit Sharing Trust""

Stock Retirement Trust financial

"Balance in the Abbott Laboratories Stock Retirement Trust as of April 28, 2026."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreland Mary K

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	04/28/2026		I		5,314	A	$94.41	17,159(1)	I	Profit Sharing Trust
Common shares without par value								104,291	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of April 28, 2026.

	/s/ Mary K. Moreland by Jessica H. Paik, Attorney-in-Fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did Abbott Laboratories (ABT) report for Mary K. Moreland?

Abbott Laboratories Executive Vice President Mary K. Moreland reported a discretionary transaction involving 5,314 common shares in a Profit Sharing Trust. The filing also shows 104,291 common shares held directly and 17,159 shares held indirectly as of April 28, 2026.

How many Abbott (ABT) shares are held indirectly in Mary K. Moreland’s trust?

The filing shows 17,159 Abbott common shares held indirectly for Mary K. Moreland in a Profit Sharing Trust. This balance reflects the position following a 5,314-share discretionary transaction under Rule 16b-3(f) as of April 28, 2026.

What price per share is disclosed in Mary K. Moreland’s Abbott (ABT) Form 4?

The Form 4 reports a price of $94.41 per Abbott common share for the 5,314-share discretionary transaction in the Profit Sharing Trust. This figure applies specifically to that trust transaction under Rule 16b-3(f) on April 28, 2026.

How many Abbott Laboratories (ABT) shares does Mary K. Moreland hold directly?

According to the Form 4, Mary K. Moreland holds 104,291 Abbott common shares directly. This figure comes from a holding entry dated April 28, 2026 and represents her direct ownership separate from shares in the Profit Sharing Trust.

What is the nature of the trust in Mary K. Moreland’s Abbott (ABT) filing?

The filing identifies a Profit Sharing Trust associated with Abbott’s Stock Retirement Trust. A footnote explains that the reported balance represents the Abbott Laboratories Stock Retirement Trust holdings as of April 28, 2026, held indirectly for Mary K. Moreland.